Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s40261-021-01026-5.pdf
Reference33 articles.
1. Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168–81.
2. Stein BL, Oh ST, Berenzon D, et al. Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol. 2015;33:3953–60.
3. Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Ann Hematol. 2015;94:901–10.
4. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008;83:359–62.
5. Mesa RA, Jamieson C, Bhatia R, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Cancer Netw. 2017;15:1193–207.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment;Journal of the Formosan Medical Association;2024-01
2. Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results;International Journal of Molecular Sciences;2023-12-28
3. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera;Experimental Hematology & Oncology;2023-06-21
4. An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1;Frontiers in Oncology;2023-04-27
5. Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera;Expert Review of Hematology;2023-04-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3